← Back to Search

Histone Deacetylase Inhibitor

Vorinostat + Chemotherapy for Cancer (NYMC195 Trial)

Phase 1
Recruiting
Led By Jeremy Rosenblum, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No active graft vs. host disease or need for immunosuppressive therapy. At least 3 months must have passed since neutrophil engraftment.
≥ 14 days since the last dose of local XRT; ≥ 6 months must have elapsed if prior TBI, craniospinal XRT or ≥ 50% radiation of pelvis; ≥ 6 wks must have elapsed if other substantial BM radiation.
Must not have
Allergy or intolerance to any of the protocol agents: vincristine, irinotecan, temozolomide, or vorinostat.
Patients who have any uncontrolled infection, positive blood culture within 48 hours prior to protocol entry, or diagnosed or receiving therapy for Clostridium difficile infection.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial tests a new mix of four medicines to treat tumors that are hard to treat with usual methods. The goal is to find the safest dose and see if this combination can effectively fight these tough tumors.

Who is the study for?
This trial is for young patients (1 to 30 years old) with relapsed or refractory solid tumors or CNS malignancies. They must have adequate organ function, not received certain treatments recently, and cannot be pregnant or breastfeeding. Those with uncontrolled infections, allergies to protocol drugs, or recent use of specific inhibitors are excluded.
What is being tested?
The study tests the highest safe dose of vorinostat combined with vincristine, irinotecan, and temozolomide in children and young adults. It aims to determine side effects, impact on tumor cell molecules, and overall treatment effectiveness against stubborn tumors.
What are the potential side effects?
Possible side effects include reactions related to each drug in the combination: vorinostat may cause fatigue and gastrointestinal issues; vincristine can lead to nerve damage; irinotecan might result in diarrhea; temozolomide could cause blood disorders.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I don't have active graft vs. host disease and haven't needed immunosuppressive therapy for over 3 months.
Select...
It's been over 14 days since my last radiation therapy, or longer for specific types.
Select...
My platelet count is above 100,000/mcL without transfusions in the last week.
Select...
I am over 16 and can do most of my daily activities on my own.
Select...
My bilirubin levels are within the normal range for my age.
Select...
My cancer has returned or didn't respond to treatment and affects either my body or brain.
Select...
My kidney function is good based on tests.
Select...
I am between 1 and 30 years old starting the treatment.
Select...
My child is under 16 and can do most activities without help.
Select...
I haven't had bone marrow-suppressing treatment in the last 3 weeks or specific chemotherapy in the last 6 weeks.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not allergic to vincristine, irinotecan, temozolomide, or vorinostat.
Select...
I do not have any uncontrolled infections or recent positive blood cultures.
Select...
I am not on any cancer treatment drugs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Vorinostat
Secondary study objectives
Overall response rate (ORR) after therapy

Side effects data

From 2011 Phase 3 trial • 661 Patients • NCT00128102
57%
Nausea
47%
Fatigue
43%
Diarrhoea
40%
Decreased appetite
40%
Vomiting
29%
Dyspnoea
24%
Constipation
20%
Weight decreased
18%
Tumour pain
18%
Cough
15%
Pleural mesothelioma malignant advanced
14%
Anaemia
12%
Pyrexia
9%
Insomnia
9%
Dry mouth
9%
Blood creatinine increased
9%
Abdominal pain
8%
Back pain
8%
Dysgeusia
7%
Oedema peripheral
7%
Dizziness
7%
Thrombocytopenia
7%
Headache
6%
Dehydration
6%
C-reactive protein increased
6%
Musculoskeletal pain
5%
Malaise
4%
Pneumonia
4%
Anxiety
3%
Rash
2%
Atrial fibrillation
2%
Accidental overdose
2%
Pleural effusion
1%
General physical health deterioration
1%
Confusional state
1%
Non-cardiac chest pain
1%
Bladder cancer
1%
Pneumothorax
1%
Sepsis
1%
Overdose
1%
Pericarditis
1%
Disseminated intravascular coagulation
1%
Death
1%
Ascites
1%
Dysphagia
1%
Pulmonary embolism
1%
Deep vein thrombosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vorinostat
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: VorinostatExperimental Treatment1 Intervention
The first cycle of chemotherapy will not include the experimental agent vorinostat. This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT. Cycle 1 * Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes. * Temozolomide: 125 mg/m2/day PO Days 1-5. * Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes. * Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8. Cycles 2-12 * Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes. * Temozolomide: 125 mg/m2/day PO Days 1-5. * Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes. * Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8. * Vorinostat: Dose per escalation schema daily Days 1-5. * Vorinostat will not be administered during Cycle 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vorinostat
2014
Completed Phase 3
~1600

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
70 Previous Clinical Trials
6,103 Total Patients Enrolled
Jeremy Rosenblum, MDPrincipal InvestigatorNew York Medical College
2 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Vorinostat (Histone Deacetylase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04308330 — Phase 1
Rhabdomyosarcoma Research Study Groups: Vorinostat
Rhabdomyosarcoma Clinical Trial 2023: Vorinostat Highlights & Side Effects. Trial Name: NCT04308330 — Phase 1
Vorinostat (Histone Deacetylase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04308330 — Phase 1
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top